natgillin/translations-raw huggingface dataset:
In 4 additional clinical trials with quetiapine, with a duration of 8 weeks in patients with moderate to severe depressive episodes in bipolar I or bipolar II disorder, Seroquel IR 300 mg and 600 mg was significantly superior to placebo treated patients for the relevant outcome measures: mean improvement on the MADRS and for response defined as at least a 50% improvement in MADRS total score from baseline.
V 4 dodatnih 8-tedenskih kliničnih preskušanjih s kvetiapinom pri bolnikih z zmernimi do hudimi depresivnimi epizodami pri bipolarni motnji I ali II je bilo zdravilo Seroquel v odmerkih 300 mg in 600 mg statistično značilno boljši od placeba pri relevantnih merilih izida: povprečnem izboljšanju MADRS in odzivu, opredeljenem kot izboljšanje celotnega seštevka MADRS za vsaj 50 % v primerjavi z izhodiščem.
PACKAGE LEAFLET
zamegljen vid
For add-on treatment of major depressive episodes in MDD:
Kot dodatno zdravljenje velikih depresivnih epizod pri veliki depresivni motnji:
Erythromycin or clarithromycin (for infections).
• eritromicin, klaritromicin (zdravila proti okužbam), • nefazodon (zdravilo proti depresiji).
Seroquel data in combination with divalproex or lithium in acute moderate to severe manic episodes at 3 and 6 weeks is limited; however, combination therapy was well tolerated.
Podatki o uporabi kvetiapina v kombinaciji z valproatom ali litijem pri zdravljenju obdobij zmerne do hude manije po 3 in 6 tednih so sicer pomanjkljivi, toda kombinirano zdravljenje so bolniki dobro prenašali.
Elevations in total cholesterol (predominantly LDL cholesterol) 12, Decreases in HDL cholesterol18, Weight gain9
zvišanje koncentracije serumskih trigliceridov11 zvišanje koncentracij celokupnega holesterola (predvsem holesterola LDL)12, znižanje holesterola HDL18, povečanje telesne mase9
A 26-week open-label extension to the acute trials (n= 380 patients), with Seroquel flexibly dosed at 400-800 mg/day, provided additional safety data.
Dodatni podatki o varnosti izvirajo iz 26-tedenskega odprtega nadaljevanja akutnih preskušanj (n = 380 bolnikov), med katerim so zdravilo Seroquel uporabljali v prilagodljivih odmerkih od 400 do 800 mg na dan.
NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussel Belgium
NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussel Belgija
Azole medicines (for fungal infections).
• nekatera zdravila proti glivičnim okužbam (iz skupine azolov),
Quetiapine exhibits minimal dystonic liability in haloperidol-sensitised or drug-naive Cebus monkeys after acute and chronic administration.
Pri opicah vrste Cebus, senzibiliziranih s haloperidolom ali naivnih za zdravila, kaže kvetiapin po akutni in kronični uporabi minimalno distonično nagnjenost.
COUNTRY
Država
In short-term placebo-controlled trials with Seroquel in paediatric patients with bipolar mania, the incidence of suicide related events was 1.0% (2/193) for quetiapine and 0% (0/90) for placebo in patients <18 years of age.
V kratkotrajnih s placebom kontroliranih preskušanjih zdravila Seroquel pri pediatričnih bolnikih z bipolarno manijo je bila incidenca s samomorom povezanih dogodkov med bolniki, starimi < 18 let, 1,0 % (2/193) pri kvetiapinu in 0 % (0/90) pri placebu.
Concomitant use of quetiapine and thioridazine caused an increased clearance of quetiapine with approx. 70%.
Sočasna uporaba kvetiapina in tioridazina je povečala očistek kvetiapina za približno
• Discontinuation symptoms (symptoms which occur when you stop taking Seroquel XR) include not being able to sleep (insomnia), feeling sick (nausea), headache, diarrhoea, being sick
• odtegnitveni sindrom (simptomi, ki se pojavijo po prenehanju jemanja zdravila Seroquel SR), ki vključuje težave s spanjem (nespečnost), slabost, glavobol, drisko, bruhanje, omotico in razdražljivost.
The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antidepressants imipramine (a known CYP 2D6 inhibitor) or fluoxetine (a known CYP 3A4 and CYP 2D6 inhibitor).
Sočasna uporaba antidepresivov imipramina (znan zaviralec CYP 2D6) ali fluoksetina (znan zaviralec CYP 3A4 in CYP 2D6) ni bistveno spremenila farmakokinetike kvetiapina.
The most commonly noted adverse reactions with quetiapine were dry mouth, sedation, and somnolence while nausea and headache were more commonly noted with the active controls.
Najpogosteje opaženi neželeni učinki kvetiapina so bili suha usta, umirjenost in zaspanost, slabost in glavobol pa je bilo pogosteje opaziti pri zdravilnih kontrolnih substancah.
The incidence of relapse was 14.2% for Seroquel XR treated patients and 34.4% for placebotreated patients.
Pri bolnikih, ki so dobivali zdravilo Seroquel SR, je bila incidenca recidivov 14,2 %, pri bolnikih, ki so dobivali placebo, pa 34,4 %.
All prolonged-release tablets are capsule shaped and marked with XR and the strength.
Izgled zdravila Seroquel SR in vsebina pakiranja Vse tablete s podaljšanim sproščanjem so ovalne oblike in označene z znakom »XR« in jakostjo.
(11) Triglycerides ≥200 mg/dL (≥2.258 mmol/L) (patients ≥18 years of age) or ≥150 mg/dL (≥1.694 mmol/L) (patients <18 years of age) on at least one occasion (12) Cholesterol ≥240 mg/dL (≥6.2064 mmol/L) (patients ≥18 years of age) or ≥200 mg/dL (≥5.172 mmol/L) (patients <18 years of age) on at least one occasion.
(11) Trigliceridi ≥ 200 mg/dl (≥ 2,258 mmol/l) (bolniki, stari ≥ 18 let) ali ≥ 150 mg/dl (≥ 1,694 mmol/l) (bolniki, stari < 18 let) vsaj v enem primeru.
The pharmacokinetics of sodium valproate and quetiapine were not altered to a clinically relevant extent when co-administered.
Farmakokinetika natrijevega valproata in kvetiapina se med njuno sočasno uporabo ni klinično pomembno spremenila.
Seroquel Depot
Norveška: Seroquel Depot
In placebo-controlled monotherapy trials in patients with a baseline neutrophil count ≥ 1.5 X 109/L, the incidence of at least one occurrence of neutrophil count <1.5 X 109/L, was 1.72% in patients treated with quetiapine compared to 0.73% in placebo-treated patients.
V preskušanjih monoterapije, kontroliranih s placebom, pri bolnikih z izhodiščnim številom nevtrofilcev ≥ 1,5 x 109/l je bila incidenca vsaj enega pojava števila nevtrofilcev < 1,5 x 109/l 1,72 % pri bolnikih, zdravljenih s kvetiapinom, in 0,73 % pri bolnikih, ki so dobivali placebo.
• The other ingredients are:
Pomožne snovi so:
There were no additional safety findings associated with treatment with Seroquel XR for up to 9 months (median 7 months).
Med terapijo z zdravilom Seroquel SR v obdobju do 9 mesecev (mediano 7 mesecev) ni bilo dodatnih izsledkov povezanih z varno uporabo zdravila.
The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine are somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and dyspepsia.
Najpogosteje opisani neželeni učinki, med uporabo kvetiapina, so zaspanost, omotica, suha usta, blaga astenija, zaprtje, tahikardija, ortostatska hipotenzija in dispepsija.
In short term, fixed dose (50mg/d to 800 mg/d), placebo-controlled studies (ranging from 3 to 8 weeks), the mean weight gain for quetiapine-treated patients ranged from 0.8 kg for the 50 mg daily dose to 1.4 kg for the 600 mg daily dose (with lower gain for the 800 mg daily dose), compared to 0.2 kg for the placebo treated patients.
V kratkotrajnih, s placebom kontroliranih študijah s stalnim odmerkom (od 50 do 800 mg/dan), ki so trajale od 3 do 8 tednov, se je bolnikom, ki so prejemali kvetiapin, telesna masa v povprečju povečala od 0,8 kg z dnevnim odmerkom 50 mg do 1,4 kg z dnevnim odmerkom 600 mg (z manjšim povečanjem z dnevnim odmerkom 800 mg); pri bolnikih, ki so prejemali placebo, je bilo to povečanje 0,2 kg.
Fatal outcome has been reported in clinical trials following an acute overdose at 13.6 grams, and in post-marketing on doses as low as 6 grams of Seroquel alone.
V kliničnih preskušanjih in v izkušnjah po trženju zdravila, kjer je bil vzet akuten prevelik odmerek 13,6 grama oziroma do 6 gramov, samega zdravila Seroquel, so poročali o smrtnih primerih.
How to store Seroquel XR Further information
Shranjevanje zdravila Seroquel SR Dodatne informacije
Elevations in serum transaminases (ALT, AST)3, decreased neutrophil count, blood glucose increased to hyperglycaemic levels 7
3, zmanjšanje števila nevtrofilcev, zvišanje glukoze v krvi do hiperglikemične ravni
Steadystate peak molar concentrations of the active metabolite norquetiapine are 35% of that observed for quetiapine.
Molarna koncentracija aktivnega presnovka norkvetiapina v stanju ravnovesja v plazmi predstavlja ob svojem vrhu 35 % koncentracije, ugotovljene za kvetiapin.
In a clinical trial, in patients with depressive episodes in bipolar I or bipolar II disorder, 300 mg/day Seroquel XR showed superior efficacy to placebo in reduction of MADRS total score.
V kliničnem preskušanju pri bolnikih z depresivnimi epizodami v okviru bipolarne motnje I ali II je zdravilo Seroquel SR v odmerku 300 mg na dan zmanjšal celotni seštevek MADRS učinkoviteje kot placebo.
For preventing recurrence of manic, mixed or depressive episodes in bipolar disorder, patients who have responded to Seroquel XR for acute treatment of bipolar disorder should continue on Seroquel XR at the same dose administered at bedtime.
Za preprečevanje ponavljanja epizod bipolarne motnje Pri bolnikih, ki so se odzvali na akutno zdravljenje bipolarne motnje z zdravilom Seroquel SR za preprečevanje recidivov maničnih, depresivnih ali mešanih epizod je priporočljivo zdravljenje nadaljevati z enakim odmerkom zdravila Seroquel SR pred spanjem.
Lot
LU
Quetiapine is extensively metabolised by the liver, with parent compound accounting for less than 5% of unchanged drug-related material in the urine or faeces, following the administration of radiolabelled quetiapine.
Po uporabi radioaktivno označenega kvetiapina gre na račun matične spojine manj kot 5 % nespremenjene, zdravilu sorodne snovi, v urin ali blato.
These include changes in the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood, decreases in the number of certain types of blood cells and increases in the amount of the hormone prolactin in the blood.
Vključno z zvišanjem določenih maščob (trigliceridov ali celokupnega holesterola) ali sladkorja v krvi ali zmanjšanjem števila določenih vrst krvnih celic ali večje količine prolaktina v krvi, kar lahko v redkih primerih povzroči: - moškim in ženskam lahko otečejo prsi in začnejo nepričakovano izločati mleko, - izostanek menstruacij ali neredne menstruacije pri ženskah
• Increase in blood pressure.
• povečanje telesne mase.
• The active substance is quetiapine.
Zdravilna učinkovina je kvetiapin.
Antidepressant effect was seen at 150 and 300 mg/day in short-term trials as add-on therapy (with amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline and venlafaxine - see Section 5.1) and at 50 mg/day in short-term monotherapy trials.
V kratkotrajnih preskušanjih kot dodatnega zdravila (z amitriptilinom, bupropionom, citalopramom, duloksetinom, escitalopramom, fluoksetinom, paroksetinom, sertralinom in venlafaksinom - glejte poglavje 5.1) je bil antidepresivni učinek opazen pri 150 in 300 mg/dan in pri 50 mg/dan v kratkotrajnih preskušanjih monoterapije.
In a short-term (9 week) study non-demented elderly patients (aged 66 to 89 years) with major depressive disorder, Seroquel XR dosed flexibly in the range of 50 mg to 300 mg/day demonstrated superior efficacy to placebo in reducing depressive symptoms as measured by improvement in MADRS total score (LS mean change vs placebo -7.54).
V kratkotrajni (9-tedenski) študiji nedementnih starejših bolnikov, starih od 66 do 89 let) z MDD, je bila učinkovitost zdravila Seroquel SR (prilagodljivo odmerjanega v razponu od 50 mg do 300 mg/dan) superiorna placebu za zmanjšanje depresivnih simptomov, merjeno z izboljšanjem celotne ocene po lestvici MADRS (povprečno zmanjšanje po metodi najmanjših kvadratov v primerjavi s placebom -7,54).
See .5.1.
Glejte poglavje 5.1. 4.
Dysphagia (See section 4.8 Undesirable effects) has been reported with quetiapine.
Med uporabo kvetiapina je bila zabeležena disfagija (glejte poglavje 4.8 Neželeni učinki).
Therefore, Seroquel XR should be used with caution in patients with known hepatic impairment, especially during the initial dosing period.
Pri bolnikih z znano okvaro jeter je zato treba zdravilo Seroquel SR uporabljati previdno, še posebej v začetnem obdobju zdravljenja.
Seroquel XR contains a substance called quetiapine.
Zdravilo Seroquel SR vsebuje učinkovino imenovano kvetiapin.
(3) Asymptomatic elevations in serum transaminase (ALT, AST) or gamma-GT-levels have been observed in some patients administered quetiapine.
(3) Pri nekaterih bolnikih, ki so dobivali kvetiapin, so opazili asimptomatsko zvišanje serumskih transaminaz (ALT, AST) ali gama-GT.
When Seroquel XR administered once daily is compared to the same total daily dose of immediate-release quetiapine fumarate (Seroquel immediate release) administered twice daily, the area under the plasma concentration-time curve (AUC) is equivalent, but the maximum plasma concentration (Cmax) is 13% lower at steady state.
uporabljenim dvakrat na dan, je površina pod krivuljo koncentracije v plazmi po času (AUC) ekvivalentna, toda največja koncentracija v plazmi je za 13 % nižja.
Occurs predominantly during the early weeks of treatment (10) The following withdrawal symptoms have been observed most frequently in acute placebo-controlled, monotherapy clinical trials, which evaluated discontinuation symptoms: insomnia, nausea, headache, diarrhoea, vomiting, dizziness, and irritability.
(10) V akutnem, s placebom kontroliranem preskušanju (monoterapija), kateri je ocenjeval umaknitvene sindrome, so opazili naslednje odtegnitvene simptome: nespečnost, slabost, glavobol, diarejo, bruhanje, omotico in razdražljivost.
In short-term, placebo-controlled bipolar depression trials the aggregated incidence of extrapyramidal symptoms was 8.9% for quetiapine compared to 3.8% for placebo.
V kratkotrajnih, s placebom kontroliranih preskušanjih pri bipolarni depresiji je bila skupna incidenca ekstrapiramidnih simptomov med uporabo kvetiapina 8,9 % in med uporabo placeba 3,8 %.
Tablet core: microcrystalline cellulose, sodium citrate, lactose monohydrate, magnesium stearate, hypromellose.
Jedro tablete: mikrokristalna celuloza (E460), natrijev citrat (E331), laktoza monohidrat, magnezijev stearat (E572), hipromeloza (E464).
The pharmacokinetics of quetiapine were not altered following co-administration with cimetidine.
Farmakokinetika kvetiapina se po sočasni uporabi s cimetidinom ni spremenila.
The same precautions observed when treating patients with major depressive episodes should therefore be observed when treating patients with other psychiatric disorders.
Ta stanja so lahko dodatno prisotna poleg velikih depresivnih epizod.Zato je treba pri zdravljenju drugih psihiatričnih motenj upoštevati enake previdnostne ukrepe kot pri zdravljenju velikih depresivnih epizod.
Medicines that have an impact on the way your heart beats, for example, drugs that can cause an imbalance in electrolytes (low levels of potassium or magnesium) such as diuretics (water pills) or certain antibiotics (drugs to treat infections).
Povejte svojemu zdravniku, če jemljete: zdravila za epilepsijo (fenitoin ali karbamazepin), zdravila proti visokemu krvnemu tlaku, barbiturate (za zdravljenje nespečnosti), tioridazin (drugo antipsihotično zdravilo), zdravila, ki vplivajo na srčni utrip, npr. zdravila, ki lahko povzročijo neravnovesje elektrolitov (nizko koncentracijo kalija ali magnezija); med takšnimi so diuretiki (tablete za odvajanje vode) in nekateri antibiotiki (zdravila za zdravljenje okužb).
In three out of four short term (up to 8 weeks) monotherapy studies, in patients with major depressive disorder, Seroquel XR 50 mg, 150 mg and 300 mg/day demonstrated superior efficacy to placebo in reducing depressive symptoms as measured by improvement in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score (LS mean change vs. placebo of 2-4 points).
V treh od štirih kratkotrajnih (do 8 tednov) študij monoterapije je Seroquel SR 50 mg, 150 mg in 300 mg/dan pri bolnikih z MDD v primerjavi s placebom pokazal superiorno učinkovitost za zmanjšanje depresivnih simptomov, merjeno s celotno oceno po lestvici MADRS (MontgomeryÅsberg Depression Rating Scale) (povprečna ocena po metodi najmanjših kvadratov v primerjavi s placebom od 2 do 4 točke).
As with other antipsychotics, weight gain, syncope, neuroleptic malignant syndrome, leucopenia, neutropenia and peripheral oedema, have been associated with quetiapine.
Tako kot druga antipsihotična zdravila je bil tudi kvetiapin povezan s povečanjem telesne mase, sinkopo, malignim nevroleptičnim sindromom, levkopenijo, nevtropenijo in perifernimi edemi.
National Competent Authorities, coordinated by the Reference Member State, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders: Update the protocols for the following ongoing Post Authorisation Safety Studies (PASSs) to collect long-term safety data of quetiapine XR in MDD patients: ¾ Modified Prescription Event Monitoring (M-PEM) Study;
posodobi protokole za naslednje študije o varnosti po odobritvi, ki še potekajo (PASS), za zbiranje podatkov o dolgoročni varnosti za kvetiapin XR pri bolnikih z MDD:
Iceland
ISIslandija
You know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines).
Če je tako, vam bo zdravnik med jemanjem zdravila Seroquel SR preverjal koncentracijo sladkorja v krvi, veste, da ste v preteklosti imeli nizko raven belih krvnih celic (kar so lahko ali pa tudi ne povzročila druga zdravila), če ste starejša oseba z demenco (poslabšanim delovanjem možganov).
The efficacy of Seroquel XR in the treatment of schizophrenia was demonstrated in one 6-week placebo-controlled trial in patients who met DSM-IV criteria for schizophrenia, and one activecontrolled Seroquel immediate release-to-Seroquel XR switching study in clinically stable outpatients with schizophrenia.
Učinkovitost zdravila Seroquel SR za zdravljenje shizofrenije so dokazali v enem 6-tedenskem s placebom kontroliranem preskušanju pri bolnikih, ki so izpolnjevali merila za shizofrenijo po DSM
Neuroleptic malignant syndrome 1
maligni nevroleptični sindrom
If you suddenly stop taking Seroquel XR, you may be unable to sleep (insomnia), you may feel sick (nausea), or you may experience headache, diarrhoea, being sick (vomiting), dizziness or irritability.
Če zdravilo Seroquel SR nehate jemati nenadoma, se lahko pojavijo nespečnost, slabost v želodcu, glavobol, driska, bruhanje, omotica ali razdražljivost.
Quetiapine is extensively metabolized by the liver.
Kvetiapin se obsežno presnovi v jetrih.
MARKETING AUTHORISATION NUMBER(S) [To be completed nationally]
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET Izpolni država članica
Seroquel XR should be administered prior to bedtime.
Zdravilo Seroquel SR je treba uporabiti pred spanjem.
Information from clinical trials has shown an increased risk of suicidal thoughts and/or suicidal behaviour in young adults aged less than 25 years with depression.
Podatki iz kliničnih preskušanj kažejo, da pri mlajših odraslih (starih manj od 25 let) z depresijo obstaja večje tveganje za pojav samomorilnega vedenja in/ali samomorilnega vedenja.
• Do not drink grapefruit juice while you are taking Seroquel XR .
• Ne pijte grenivkinega soka, medtem ko jemljete zdravilo Seroquel SR. Grenivkin sok lahko vpliva na delovanje zdravila.
6.4 Special precautions for storage This medicinal product does not require any special storage conditions.
Za shranjevanje zdravila niso potrebna posebna navodila.
Contains lactose monohydrate.
Pomožna snov: laktoza monohidrat.
This medicinal product is authorised in the Member States of the EEA under the following names:
To zdravilo je odobreno v državah članicah EGP pod naslednjimi imeni: Avstrija: Seroquel XR
In placebo-controlled clinical trials with children and adolescent patients treated with Seroquel, quetiapine was associated with an increased incidence of extrapyramidal symptoms (EPS) compared to placebo in patients treated for schizophrenia and bipolar mania (see section 4.8).
V kliničnih, s placebom kontroliranih preskušanjih zdravljenja shizofrenije in bipolarne motnje z zdravilom Seroquel pri otrocih in mladostnikih je kvetiapin spremljala večja incidenca ekstrapiramidnih simptomov (EPS) kot placebo (glejte poglavje 4.8).
SE - Sweden AstraZeneca AB AstraZeneca Sverige SE-151 85 Södertälje Sweden
SE-151 85 Södertälje Švedska
Do not split, chew or crush the tablets.
Tablet ne lomite, ne grizite in ne drobite.
Blood and lymphatic system disorders
Bolezni krvi in limfatičnega sistema Pogosti:
Iron oxide, yellow (E172) (50, 200 and 300 mg tablets) Iron oxide, red (E172) (50 mg tablets) 6.2 Incompatibilities
Obloga hipromeloza (E464) makrogol titanov dioksid (E171) rumen železov oksid (E172) (50-, 200- in 300-mg tablete) rdeč železov oksid (E172) (50-mg tablete)
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Izponi država članica
The pharmacokinetics of lithium were not altered when co-administered with quetiapine.
Farmakokinetika litija se med sočasno uporabo s kvetiapinom ni spremenila.
In a short-term placebo-controlled monotherapy trial in elderly patients with major depressive disorder, the aggregated incidence of extrapyramidal symptoms was 9.0% for Seroquel XR and 2.3% for placebo.
V kratkotrajnih, s placebom kontroliranih kliničnih preskušanjih monoterapije pri starejših bolnikih z MDD je bila skupna incidenca ekstrapiramidnih simptomov med uporabo zdravila Seroquel SR 9,0 % in med uporabo placeba 2,3 %.
In placebo controlled clinical trials of adult patients quetiapine was associated with an increased incidence of extrapyramidal symptoms (EPS) compared to placebo in patients treated for major depressive episodes in bipolar disorder and major depressive disorder (see sections 4.8 and 5.1).
V kliničnih, s placebom kontroliranih preskušanjih je bil kvetiapin med zdravljenjem depresivnih epizod pri bipolarni motnji in MDD povezan z večjo incidenco ekstrapiramidnih simptomov (EPS) kot placebo (glejte poglavji 4.8 in 5.1).
Metabolism and nutritional disorders Very common:
Presnovne in prehranske motnje Pogosti:
Extrapyramidal Symptoms
Ekstrapiramidni simptomi
1 blister of 10 tablets
1 pretisni omot, ki vsebuje 10 tablet
The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antipsychotics risperidone or haloperidol.
Sočasna uporaba antipsihotikov risperidona ali haloperidola ni bistveno spremenila farmakokinetike kvetiapina.
In short-term placebo-controlled clinical trials with Seroquel in paediatric patients with schizophrenia, the incidence of suicide related events was 1.4% (2/147) for quetiapine and 1.3% (1/75) for placebo in patients <18 years of age.
Samomor/samomorilne misli ali klinično poslabšanje V kratkotrajnih s placebom kontroliranih kliničnih preskušanjih zdravila Seroquel pri pediatričnih bolnikih s shizofrenijo je bila incidenca s samomorom povezanih dogodkov med bolniki, starimi < 18 let, 1,4 % (2/147) pri kvetiapinu in 1,3 % (1/75) pri placebu.
Do not take Seroquel XR if: you are allergic (hypersensitive) to quetiapine or any of the other ingredients of Seroquel XR (see section 6: Further information) you are taking any of the following medicines: - some medicines for HIV - azole medicines (for fungal infections) - erythromycin or clarithromycin (for infections) - nefazodone (for depression).
Dodatne informacije); če uporabljate katero od naštetih zdravil: - nekatera zdravila za zdravljenje HIV, - nekatera zdravila proti glivičnim okužbam (iz skupine azolov), - eritromicin, klaritromicin (zdravila proti okužbam), - nefazodon (zdravilo proti depresiji).
Seroquel Depot United Kingdom Seroquel XL
Slovenija: Seroquel SR Španija: Seroquel Prolong Švedska: Seroquel Depot Velika Britanija: Seroquel XL
GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, AND PACKAGE LEAFLET
PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA IN NAVODIL ZA UPORABO